Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

• Status: Not yet recruiting
• Trial end date: 2025-12-30
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Kansas Medical Center
• Treatments: Bupropion

Criteria

Inclusion Criteria:

Eligible individuals must be self-described African American, age >18 years, interested in quitting, smoked >1 cpd for >1 years and smoked on >25 days in the past month, willing to take 6 months of study medication and complete all visits, have a home address and functioning telephone number.

Exclusion Criteria:

Consistent with contraindications for bupropion: use of psychoactive medications; history of alcohol or substance abuse within the past year; binge drinking (>5 drinks on one occasion) >2 times in the past month; history of seizures or head trauma; history of bulimia or anorexia nervosa; pregnant (as measured by over the counter pregnancy test kit for women of child-bearing age only) or contemplating pregnancy; breast feeding; myocardial infarction in the past 2 months; reported use of opiates, cocaine, or stimulants; unstable diabetes. Bupropion is a known inhibitor of the liver enzyme CYP2D6, so those taking drugs known to be higher metabolized by this enzyme (e.g., metoprolol, tamoxifen) will be excluded. Other exclusions include use of stop smoking medications (bupropion, varenicline, nicotine replacement, fluoxetine, clonidine, buspirone, or doxepin) in the past 30 days, planning to move from the Kansas City area in the next year, or other smoker in household enrolled in the study.